DOA REMEDIOS T.

ROMUALDEZ MEDICAL FOUNDATION TACLOBAN CITY COLLEGE OF NURSING PHARMACOLOGY COURSE DESCRIPTION: This course deals with pharmacodynamics, pharmacokinetics and clinical therapeutic uses of drugs. Emphasis is given on how a drug works to anticipate when giving a drug to a patient are of paramount importance since nursing responsibilities include administering drugs, assessing drug effects, intervening to make a drug more tolerable and providing teachings about drug and drug regimen. COURSE CREDIT: 3 UNITS LECTURE CONTACT HOURS/ SEM: 54 LECTURE HOURS PREREQUISITE: Math I, General Chemistry, Anatomy and Physiology, NCM 102 PLACEMENT: 2ND YEAR, 2ND SEMESTER DATE January 18 TOPIC INTRODUCTION TO PHARMACOLOGY INSTRUCTOR MS. ULBATA

I.

1. Pharmacology 2. Pharmacology and Therapeutics 3. Classification of therapeutic Agents as Drugs, Biologics, and alternative Therapies 4. Prescription and Over the Counter Drugs 5. Drug Regulations and Standards 6. Sources and Evaluation of Drugs 7. Legal Regulation of Drugs 8. Drug Classes and Schedules A. DRUG AND THE BODY 1. Pharmacokinetics 2. Pharmacodynamics 3. Factors Influencing Drug Effects B. TOXIC EFFECTS OF DRUGS 1. Adverse Effects 2. Drug Allergy 3. Drug-Induced Tissue and Organ Damage C. NURSING MANAGEMENT THE NURSING PROCESS a. ASSESSMENT Subjective data a. History - Health History Assessment Questions Pertinent to Drug Administration Objective Data a. Physical Assessment b. Laboratory Values c. Medication Effects b. NURSING DIAGNOSIS c. PLANNING d. IMPLEMENTATION - Principles of Drug Administration - Proper Drug Administration

- Comfort Measures - Patient and Family Education e. EVALUATION January 23 (THURSDAY), 25 D. DOSAGE CALCULATIONS E. DRUG ADMINISTRATION THROUGHOUT THE LIFESPAN PHARMACOTHERAPY ACROSS THE LIFESPAN PREGNANT CLIENT LACTATING CLIENT PEDIATRICS ADULTHOOD MS. ULBATA

1. 2. 3. 4.

F. MEDICATION ERRORS AND RISK REDUCTION 1. Medication Errors

FEBRUARY 1

II.

CONCEPT OF IMMUNOLOGY AND INFLAMMATORY PROCESSES THE IMMUNE SYSTEM - Nonspecific Body Defenses and Immune Responses - Humoral Immunity and Antibodies - Cell mediated Immunity and Cytokines - Nursing Process

MR. DE VEYRA

A. IMMUNE SYSTEM MODULATORS 1. Vaccines 2. Immunostimulants 3. Immunosuppresants CONCEPT ON INFLAMMATION - Function of Inflammation - Role of Histamine in Inflammation - Histamine Receptors - Nursing Process B. ANTIINFLAMMATORY AGENTS 1. Nonsteroidal anti-inflammatory drugs 2. Systemic Glucocorticoids 3. Antipyretics - Mechanism of Action - Therapeutic actions and indication - Pharmacokinetics - Contraindications and Cautions - Adverse Effects - Clinically important drug-drug interaction - Nursing Process - Patient Teaching List a. NSAIDS C. ANTIINFECTIVE AGENTS 1. Pathogenenicity and Virulence 2. Description and Classification of Bacteria 3. Antiinfective Drugs 4. Acquired Resistance 5. Selection of effective antibiotics 6. Host Factors

7. Antibacterial Agents - Penicillins - Cephalosporins - Tetracyclines - Macrolides - Aminoglycosides - Fluoroquinolones - Sulfonamides - Antituberculosis Agents FEBRUARY 6 (THURSDAY), 8 D. ANTIVIRAL AGENTS 1. Characteristics of Viruses 2. HIV/AIDS 3. General Principles of HIV Pharmacotherapy 4. Classification of Drugs for HIV/ AIDS - Reverse Transcriptase Inhibitors - Protease Inhibitors 5. Pharmacotherapy a. Herpes Virus Infections b. Influenza c. Viral Hepatitis E. ANTIFUNGAL AGENTS 1. Characteristics of Fungi 2. Classifications of Mycoses 3. Mechanism of Action 4. Nursing Process 5. Antifungal Agents - Systemic - Superficial F. ANTIPROTOOAL AGENTS a. Malarial Drugs b. Nonmalarial Drugs G. ANTIHELMINTIC DRUGS H. ANTINEOPLASTIC AGENTS 1. Characteristic of Cancer: Uncontrolled Cell Growth 2. Causes of Cancer 3. Treatment of Cancer 4. Growth Fraction and Success of Chemotherapy 5. Special Pharmacotherapy Protocols and Strategies for Cancer Chemotherapy 6. Toxicity of Antineoplastic Agents 7. Classification of Antineoplastic Agents FEBRUARY 15 III. CONCEPT ON METABOLIM FUNCTIONAL HEALTH PATTERN NUTRITION AND METABOLIC PATTERN 1. Overview a. GI System b. Acid Production by the stomach c. Peptic Ulcer Disease 2. Drug Therapy a. Antiulcer Drugs b. Laxatives c. Antispasmodics d. Antiemetics MR. DE VEYRA MR. DE VEYRA

FEBRUARY 22

IV.

THE ENDOCRINE SYSTEM AND HOMEOSTASIS a. Drugs acting on the Endocrine System - Hypothalamic and Pituitary Agents - Hypothalamic Releasing Agents - Anterior Pituitary Hormones b. Drug Therapy - Growth Hormone - Growth Hormone Antagonist - Posterior Pituitary Hormones - Adrenocortical Agents - Thyroid and Parathyroid Hormones - Antidiabetic Agents a. Glucose regulation b. Diabetes Mellitus c. Drug Therapy - Insulin - Oral Antidiabetic Agents

MR. DE VEYRA

MARCH 1

V.

CONCEPT OF FLUID AND ELECTROLYTES FUNCTIONAL HEALTH PATTERN

MR. DE VEYRA

ELIMINATION PATTERN 1. Overview of the Renal System a. Renal absorption and Secretion b. Fluid and Elctrolyte Balance c. Renal Failure 2. Drug Acting on the Renal System a. Diuretics b. Urinary Tract Agents c. Parenteral Fluids and Electrolytes

MARCH 8

VI.

CONCEPT ON PERCEPTION AND COORDINATION THE NERVOUS SYSTEM a. Central Nervous System b. Peripheral Nervous System b.1 Autonomic Nervous System - Sympathetic - Paraympathetic

MS. ULBATA

A. DRUGS AFFECTING THE ANS a. Adrenergic Agents b. Adrenergic Blocking Agents c. Cholinergic Agents d. Cholinergic Blocking Agents B. DRUGS ACTING ON THE CNS AND PNS A. ANXIOLYTICS AND HYPNOTIC AGENTS 1. States affected by anxiolytic and hypnotic drugs 2. Drug Therapy a. Benzodiazepines - Antidote b. Barbiturates B. ANTIDEPRESSANT DRUGS 1. Depression and Antidepressant 2. Drug Therapy

3. Tricyclic Depressants 4. MAOIs 5. SSRIs MARCH 15 MARCH 22 MIDTERM EXAMINATION C. PYCHOTHERAPEUTIC AGENTS 1. Mental Disorders and their Classification 2. Psychotherapeutic Drugs a. Antipsychotic Neuroleptic Drugs b. Antimanic Drugs c. CNS Stimulants D. ANTIEPILEPTIC DRUGS 1. Nature of Epilepsy 2. Drugs for treating Tonic-Clonic Seizures 3. Drugs for Treating Absence Seizures MARCH 27 (THURSDAY) DEGENERATIVE DISEASES OF THE CENTRAL NERVOUS SYSTEM E. ANTIPARKINSONISM AGENTS 1. Parkinsonism 2. Drug Therapy a. Anticholinergics b. Dopaminergics - Adjuncts to Levodopa Therapy F. MUSCLE RELAXANTS 1. Nerves and Movements 2. Neuromuscular Abnormalities 3. Drug Therapy - Centrally Acting Skeletal Muscle Relaxants - Direct Acting Skeletal Antispasmodic G. NARCOTICS AND ANTIMIGRAINE DRUGS 1. Pain Perception 2. Migraine Headache 3. Drug Therapy a. Narcotics b. Opiod Receptors c. Narcotic Agonists d. Narcotic Agonist Antagonist e. Narcotic Antagonist f. Ergot Derivatives g. Triptans MARCH 29 H. GENERAL AND LOCAL ANESTHETICS 1. Local Anesthesia 2. General Anesthesia 3. Drug Therapy I. NEUROMUSCULAR AGENTS 1. Neuromuscular Junction 2. Drug Therapy a. Nondepolarizing Neuromuscular Junction Blockers b. Depolarizing Neuromuscular Junction Blockers MS. ULBATA MS. ULBATA MS. ULBATA

APRIL 5

VII.

CONCEPTS ON OXYGENATION, PERFUSION FUNCTIONAL HEALTH PATTERN

MS. ULBATA

DRUGS ACTING ON THE CARDIOVASCULAR SYSTEM 1. Overview : Cardiovascular System 2. ANTIHYPERTENSION a. Renin-Angiotensin System b. Blood Pressure Control c. Hormonal and Nervous System Factors Influencing Blood Pressure d. Primary Factors affecting BP e. Drug Therapy A. ANTIHYPERTENSIVE DRUGS 1. ACE Inhibitors 2. Angiotensin II Receptor Blocker 3. Calcium Channel Blockers 4. Vasodilators 5. Diuretics 6. Beta Blockers 7. Hypotensive Agents B. ANTIARRHYTHMIC AGENTS 1. Overview a. Cardiac Conduction b. Automaticity of the heart c. Cardiac Arrhythmias 2. Drug Therapy a. Class I: Sodium Channel Blockers b. Class II : Beta Adrenergic Antagonist c. Class III: Potassium Channel Blockers d. Class IV: Calcium Channel Blockers C. ANTIANGINAL AGENTS 1. Overview a. Blood Supply to Myocardium b. Coronary Artery Disease 2. Drug Therapy a. Nitrates b. Beta-Adrenergic Blockers c. Calcium Channel Blockers APRIL 10 (THURSDAY) D. CARDIOTONIC AGENTS 1. Overview a. Cardiac Muscle Function b. Congestive Heart Failure 2. Drug Therapy a. Vasodilators b. Diuretics c. Beta-Adrenergic Agonists d. Cardiotonic Agents - Cardiac Glycosides e. Phophodiesterase Inhibitors E. LIPID LOWERING AGENTS 1. Overview a. Metabolism of Fats b. Coronary Artery Disease 2. Drug Therapy a. HMG-COA Reductase Inhibitors b. Bile Acid Binding Agents MS. ULBATA

A.

c. Fibric Acid Agents d. Other Agents APRIL 12 F. DRUG AFFECTING BLOOD COAGULATION 1. Overview a. Blood Coagulation b. Clot Resolution and Anticlotting 2. Drug Therapy: Hematopietic Growth Factor a. Epoetin Alfa b. Colony Stimulating Factor c. Platelet Enhancers - Vitamin K: Reversing Warfarin Effects - Protamine Sulfate: Antidote for Heparin Overdose - Lepirudin: Treating Heparin Allergy G. DRUGS USED TO TREAT ANEMIA 1. Overview a. Blood Components b. Erythropoiesis c. Anemia 2. Drug Therapy a. Iron Supplement MR. DE VEYRA APRIL 26 H. DRUG AFFECTING THE RESPIRATORY SYSTEM 1. Overview a. Respiratory System b. Respiratory Pathology 2. Drug Therapy a. Bronchodilators b. Antiinflammatory Drugs for Asthma c. Epectorants d. Mucolytics e. Antitussive Drugs MR. DE VEYRA

MAY 3

FINAL EXAMINATION

TOTAL OF 54 hrs ( 3 hrs per week except those where Thursday classes (9am-12nn) is indicated to complete the total number of hours [ 54hours] in 16 weeks. ) SCHEDULE: LECTURE DAYS: SATURDAYS: THURDAYS: MS. ULBATA/ MR. DE VEYRA 1:00 PM 4:00 PM 9:00 AM 12:00 NN (TO COMPLETE THE NUMBER OF LECTURE HOURS [ 54 hrs]

REFERENCES: 1. Kee, Joyce, E. Hayes, L. McCuistion, Pharmacology: A Nursing Process Approach 2. Karch, A.. Focus on Nursing Pharmacology 3. Clayton, Bruce and Y. Stock, Baic Pharmacology for Nurses